Health Care & Life Sciences » Biotechnology | Achillion Pharmaceuticals Inc.

Achillion Pharmaceuticals Inc.

Achillion Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
138.59 M
Public Float
134.33 M
Achillion Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.49
Market Cap
$375.95 M
Shares Outstanding
138.73 M
Public Float
134.93 M

Profile

Address
VEVA Building 14
Blue Bell Pennsylvania 19422
United States
Employees -
Website http://www.achillion.com
Updated 07/08/2019
Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

Financials

View All

Joseph Truitt
President, Chief Executive Officer & Director
David I. Scheer
Chairman